Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

An ‘International’ investment
November 2019
SHARING OPTIONS:

ANN ARBOR, Mich.—Last month saw NSF International acquire a majority interest in Amarex Clinical Research LLC. Moving forward, Amarex will be known as Amarex Clinical Research LLC, an NSF International company. The transaction provides Amarex with access to NSF’s expert network and global footprint, and as part of the latter’s organization, Amarex will support companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.
 
Amarex founder Dr. Kazem Kazempour, who will continue as president and CEO, said: “NSF International’s operational excellence will accelerate our expert team’s leap forward in the CRO market, and better help pharmaceutical, biotech and medical device/diagnostic companies develop products and services that will protect and improve human health while minimizing inefficiencies to save time and reduce unnecessary costs.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.